<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462876</url>
  </required_header>
  <id_info>
    <org_study_id>FPR14-03</org_study_id>
    <nct_id>NCT02462876</nct_id>
  </id_info>
  <brief_title>Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)</brief_title>
  <official_title>Post-market Study: Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the long term safety and performance of the GORE® VIABAHN®
      Endoprosthesis for the treatment of patients with Popliteal Artery Aneurysms.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as blood flow without occlusion maintained through the device after implant without an intervention evaluated at 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as serious adverse events and adverse events related to the study procedure or the study device through 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Defined as blood flow without occlusion maintained through the device after implant without an intervention and estimated through time-to-event analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety at 24 and 36 Months</measure>
    <time_frame>24 and 36 months</time_frame>
    <description>Serious Adverse Events and Adverse Events Related to Study Procedure or Study Device through 24 and 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>During hospitalization, approximately 1-2 days</time_frame>
    <description>The number of days the subject remains in the hospital due to endovascular repair of a popliteal artery aneurysm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Procedure</measure>
    <time_frame>During procedure, approximately 120 minutes</time_frame>
    <description>The number of minutes the subject remains in the operating room or catheterization laboratory due to endovascular repair of a popliteal artery aneurysm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Defined as blood flow maintained through the device after implant regardless of repeat interventions performed (without occlusion) and estimated through time-to-event analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Limb Loss</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Limb loss is defined as the amputation of the study limb above the metatarsals. Freedom from limb loss will be estimated through time-to-event analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Repeat Intervention</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Repeat Intervention is defined as any endovascular or surgical procedure performed to treat a stenosis or occlusion with the study device(s) or within 5 millimeters of the proximal or distal edge of the device(s), treatment of endoleaks or other reasons. Freedom from Repeat Intervention will be estimated through time-to-event analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>12, 24, and 36 months</time_frame>
    <description>Defined as blood flow through the device regardless of repeat interventions performed (with or without occlusion) and freedom from surgical bypass. Secondary Patency will be estimated through time-to-event analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Post-procedure at day 30</time_frame>
    <description>Defined as successful aneurysmal exclusion using the study device at time of the procedure without Type I or III endoleaks that require post-procedure intervention within 30 days.</description>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Popliteal Artery Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® VIABAHN® Endoprosthesis</intervention_name>
    <description>Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the
        popliteal artery, or presence of mural thrombus (&lt; 2 cm) in the popliteal artery treated
        since the date of reimbursement in France.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion to the study requires the patient:

          1. Received a GORE® VIABAHN® Endoprosthesis to treat a popliteal artery aneurysm

          2. Had a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal
             artery, or the presence of mural thrombus (&lt; 2 cm) in the popliteal artery;

          3. Was 18 years of age or older at the time of the treatment;

          4. Had an elective popliteal artery aneurysm procedure;

          5. Has provided Informed Consent, personally or through lawful representation as
             determined by applicable local regulations and state law

        Exclusion Criteria:

        Prior to or at the time of implant the patient is / has:

          1. Bilateral popliteal artery aneurysms with initial treatment on the same day;

          2. Thrombotic occlusion of the popliteal artery or PAA;

          3. Marfan syndrome or Ehlers-Danlos syndrome;

          4. Unable to tolerate antiplatelet therapy;

          5. Thrombophilia requiring long term anticoagulation;

          6. Known allergies to the GORE® VIABAHN® Endoprosthesis components;

          7. Enrolled in another investigational drug or medical device trial where participation
             may have affected the outcome or treatment of the subject in the popliteal artery
             aneurysm study with the GORE® VIABAHN® Endoprosthesis or had previous surgery for the
             popliteal artery aneurysm in the study limb.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil Chakfé</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaire de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>June 4, 2020</results_first_submitted>
  <results_first_submitted_qc>July 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2020</results_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02462876/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02462876/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Viabahn</title>
          <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgical Bypass</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Amputation Above the Metatarsals</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Viabahn</title>
          <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Patency at 12 Months</title>
        <description>Defined as blood flow without occlusion maintained through the device after implant without an intervention evaluated at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all subjects who lost patency within 12 months and all patent subjects with at least a 12 month visit or later.</population>
        <group_list>
          <group group_id="O1">
            <title>Viabahn</title>
            <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency at 12 Months</title>
          <description>Defined as blood flow without occlusion maintained through the device after implant without an intervention evaluated at 12 months.</description>
          <population>Includes all subjects who lost patency within 12 months and all patent subjects with at least a 12 month visit or later.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patent at 12 Months</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Patent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety at 12 Months</title>
        <description>Defined as serious adverse events and adverse events related to the study procedure or the study device through 12 months</description>
        <time_frame>12 months</time_frame>
        <population>Includes all subjects who have a serious adverse event or adverse event related to study procedure or device within 12 months and all subjects free from those events with at least a 12 month visit or later.</population>
        <group_list>
          <group group_id="O1">
            <title>Viabahn</title>
            <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Safety at 12 Months</title>
          <description>Defined as serious adverse events and adverse events related to the study procedure or the study device through 12 months</description>
          <population>Includes all subjects who have a serious adverse event or adverse event related to study procedure or device within 12 months and all subjects free from those events with at least a 12 month visit or later.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No Event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Event(s)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Patency</title>
        <description>Defined as blood flow without occlusion maintained through the device after implant without an intervention and estimated through time-to-event analysis</description>
        <time_frame>12, 24, and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety at 24 and 36 Months</title>
        <description>Serious Adverse Events and Adverse Events Related to Study Procedure or Study Device through 24 and 36 months.</description>
        <time_frame>24 and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <description>The number of days the subject remains in the hospital due to endovascular repair of a popliteal artery aneurysm</description>
        <time_frame>During hospitalization, approximately 1-2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Viabahn</title>
            <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <description>The number of days the subject remains in the hospital due to endovascular repair of a popliteal artery aneurysm</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Days in Hospital = 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Days in Hospital = 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Days in Hospital = 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Days in Hospital = 4 or more</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Procedure</title>
        <description>The number of minutes the subject remains in the operating room or catheterization laboratory due to endovascular repair of a popliteal artery aneurysm.</description>
        <time_frame>During procedure, approximately 120 minutes</time_frame>
        <population>Subjects with missing procedure times are not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Viabahn</title>
            <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Procedure</title>
          <description>The number of minutes the subject remains in the operating room or catheterization laboratory due to endovascular repair of a popliteal artery aneurysm.</description>
          <population>Subjects with missing procedure times are not included.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" spread="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Primary Assisted Patency</title>
        <description>Defined as blood flow maintained through the device after implant regardless of repeat interventions performed (without occlusion) and estimated through time-to-event analysis.</description>
        <time_frame>12, 24, and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Limb Loss</title>
        <description>Limb loss is defined as the amputation of the study limb above the metatarsals. Freedom from limb loss will be estimated through time-to-event analysis.</description>
        <time_frame>12, 24, and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Repeat Intervention</title>
        <description>Repeat Intervention is defined as any endovascular or surgical procedure performed to treat a stenosis or occlusion with the study device(s) or within 5 millimeters of the proximal or distal edge of the device(s), treatment of endoleaks or other reasons. Freedom from Repeat Intervention will be estimated through time-to-event analysis.</description>
        <time_frame>12, 24, and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency</title>
        <description>Defined as blood flow through the device regardless of repeat interventions performed (with or without occlusion) and freedom from surgical bypass. Secondary Patency will be estimated through time-to-event analysis.</description>
        <time_frame>12, 24, and 36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Defined as successful aneurysmal exclusion using the study device at time of the procedure without Type I or III endoleaks that require post-procedure intervention within 30 days.</description>
        <time_frame>Post-procedure at day 30</time_frame>
        <population>Subjects who are not technical failures must have at least 31 days of follow-up in order to be considered a technical success.</population>
        <group_list>
          <group group_id="O1">
            <title>Viabahn</title>
            <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Defined as successful aneurysmal exclusion using the study device at time of the procedure without Type I or III endoleaks that require post-procedure intervention within 30 days.</description>
          <population>Subjects who are not technical failures must have at least 31 days of follow-up in order to be considered a technical success.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Success</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months (interim results to-date)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Viabahn</title>
          <description>Subjects with popliteal artery aneurysm treated with Gore Viabahn endoprosthesis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Anemia iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coronaropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Endoleak</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>False aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aneurysm repair</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral-tibial arterial bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoropopliteal artery bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal aneurysm, ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Aneurysm enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischaemic limb pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischemia peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ischemic limb pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leg ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Popliteal artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Novak</name_or_title>
      <organization>W. L. Gore &amp; Associates</organization>
      <phone>314-440-2119</phone>
      <email>enovak@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

